{'fraction_non_alphanumeric': 0.02711323763955343, 'fraction_numerical': 0.030303030303030304, 'mean_word_length': 4.869158878504673, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rieger syndrome is not associated with PAX6 deletion: a correction to Acta Ophthalmol Scand 2001: 79: 201–203

and human leukocyte antigen B-27). No other factors causing the uveitis were found. We suspect that the uveitis was a side-effect of the cytostatic drug. We believe that our case of uveitis is similar to that reported by Planer et al. (2004). In our opinion these cases represent the end of the spectrum of ophthalmological involvement secondary to high-dose Ara–C and highlight the importance of prompt referral to an ophthalmologist whenever patients receiving this drug develop ocular symptoms suggesting uveitis.